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Type 2 diabetes mellitus (T2DM) increases risk for dementia, including Alzheimer’s
disease (AD). Many previous studies of brain changes underlying cognitive impairment
in T2DM have applied conventional structural magnetic resonance imaging (MRI) to
detect macrostructural changes associated with cerebrovascular disease such as white
matter hyperintensities or infarcts. However, such pathology likely reflects end-stage
manifestations of chronic decrements in cerebral blood flow (CBF). MRI techniques
that measure CBF may (1) elucidate mechanisms that precede irreversible parenchymal
damage and (2) serve as a marker of risk for cognitive decline. CBF measured with
arterial spin labeling (ASL) MRI may be a useful marker of perfusion deficits in T2DM
and related conditions. We examined associations among T2DM, CBF, and cognition
in a sample of 49 well-characterized nondemented older adults. Along with a standard
T1-weighted scan, a pseudocontinuous ASL sequence optimized for older adults (by
increasing post-labeling delays to allow more time for the blood to reach brain tissue)
was obtained on a 3T GE scanner to measure regional CBF in FreeSurfer derived regions
of interest. Participants also completed a neuropsychological assessment. Results
showed no significant differences between individuals with and without T2DM in terms of
cortical thickness or regional brain volume. However, adjusting for age, sex, comorbid
vascular risk factors, and reference CBF (postcentral gyrus) older adults with T2DM
demonstrated reduced CBF in the hippocampus, and inferior temporal, inferior parietal,
and frontal cortices. Lower CBF was associated with poorer memory and executive
function/processing speed. When adjusting for diabetes, the significant associations
between lower regional CBF and poorer executive function/processing speed remained.
Results demonstrate that CBF is reduced in older adults with T2DM, and suggest
that CBF alterations likely precede volumetric changes. Notably, relative to nondiabetic
control participants, those with T2DM showed lower CBF in predilection sites for AD
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pathology (medial temporal lobe and inferior parietal regions). Findings augment
recent research suggesting that perfusion deficits may underlie cognitive decrements
frequently observed among older adults with T2DM. Results also suggest that CBF
measured with ASL MRI may reflect an early and important marker of risk of cognitive
impairment in T2DM and related conditions.
Keywords: aging, diabetes, vascular risk, arterial spin labeling, cerebral blood flow, neuropsychology, memory,
Alzheimer’s disease
INTRODUCTION
Type 2 diabetes mellitus (T2DM) is a chronic, highly disabling
metabolic disorder that is growing in prevalence at an alarming
rate. In 2015, it was estimated that 30.3 million Americans
(1 in 10) had either diagnosed or undiagnosed diabetes, the
vast majority of whom (90–95%) had T2DM (Prevention,
2017). This is particularly concerning, given that T2DM has
been linked to an increased risk for developing mild cognitive
impairment (MCI) and dementia including Alzheimer’s disease
(AD) (Luchsinger et al., 2001; Arvanitakis et al., 2004; Luchsinger
et al., 2007; Vagelatos and Eslick, 2013) – conditions that
are associated with high health care costs, reduced quality of
life, and loss of independence in late adulthood. Even among
nondemented older adults, studies have observed increased
rates of subtle cognitive impairment and accelerated cognitive
decline in individuals with T2DM compared to their nondiabetic
counterparts, suggesting that cognitive impairment may be a
chronic long-term complication of T2DM (Geijselaers et al.,
2015). In T2DM, vascular dysfunction has long been considered
the underlying cause of the multi-organ complications of the
disease. Cerebrovascular dysfunction, thus, seems to be a possible
mechanism by which poor cognitive outcomes occur in diabetes.
Indeed, neuropathologic studies have linked T2DM to increased
incidence of cerebral infarcts (Peila et al., 2002; Arvanitakis
et al., 2006; Sarwar et al., 2010). Furthermore, insulin resistance,
hyperglycemia, and inflammation – all which represent defining
deleterious metabolic states that occur in diabetes – have been
linked to cerebrovascular dysfunction (Brownlee, 2005; Zhou
et al., 2014; Chung et al., 2015).
Most previous studies of brain changes underlying cognitive
decrements in T2DM have applied conventional structural
magnetic resonance imaging (MRI) to detect macrostructural
changes associated with cerebral gray matter (GM) atrophy
and markers of cerebrovascular disease (CVD) lesions such
as white matter hyperintensities (WMH), which are thought
to reflect small vessel disease. Many structural neuroimaging
studies have shown in vivo cerebral atrophy in T2DM that has
been linked to poorer cognitive performance across domains
including memory, executive functioning, and processing speed
(Tiehuis et al., 2009; Hayashi et al., 2011; Moran et al., 2013;
Zhang et al., 2014). Results from several of these studies
indicate that regional atrophy patterns in T2DM resemble those
seen in preclinical AD, with hippocampal atrophy identified
as the earliest and most prominent neurodegenerative change
(Moran et al., 2013). However, these structural brain changes
in T2DM likely reflect end-stage manifestations of chronic
decrements in cerebrovascular functioning. Advanced functional
MRI techniques that measure cerebral blood flow (CBF) may
elucidate the mechanisms that precede the development of
irreversible parenchymal damage and serve as an early indicator
of impending cognitive decline in at-risk populations.
Arterial spin labeling (ASL) is a non-invasive MRI technique
that measures CBF alterations. ASL studies of AD demonstrate
similar patterns of regional perfusion compared to studies using
fluorodeoxyglucose positron emission tomography (FDG-PET)
and single photon emission computed tomography (SPECT)
(Chen et al., 2011; Takahashi et al., 2014). ASL techniques have
advantages over PET and SPECT, however, related to the nature
of the tracer (i.e., magnetically labeled arterial water) (Detre and
Alsop, 1999). That is, ASL employs a non-invasive, endogenous
tracer rather than an intravenously administered contrast agent.
The rapid decay time of the magnetized water molecules (on
the order of seconds), moreover, allows for relatively brief scan
times (5–10 min) that can provide dynamic CBF estimates
with high temporal resolution (Johnson et al., 2005). These
advantages, combined with its ability to quantitatively measure
cerebral perfusion (in milliliters per 100 g of tissue per minute),
make ASL an ideal technique for research and clinical settings
(Telischak et al., 2015) designed to monitor neural and vascular
changes in healthy older adults (Bangen et al., 2009) and clinical
populations (Johnson et al., 2005; Xu et al., 2007; Bangen et al.,
2012; Binnewijzend et al., 2013).
There are few publications examining cerebral perfusion and
its associations with cognition in individuals with T2DM, and
findings across these limited studies are contradictory. In one
of the earliest studies, Dandona et al. (1978) measured global
CBF by the 133-Xe inhalation method in 59 individuals with
T2DM and 28 controls encompassing a wide range of ages.
They reported age-related perfusion reductions that were similar
in those with and without T2DM. Previous studies employing
SPECT have reported that diabetic patients exhibit decreased
CBF (Wakisaka et al., 1990; Nagamachi et al., 1994; Sabri et al.,
2000) and that these CBF reductions are associated with poorer
cognitive performance (Xia et al., 2015). Although the extant
literature still remains relatively limited, a handful of studies
have attempted to employ ASL to assess associations among
diabetes status, CBF, and cognitive functioning. Consistent with
the PET and SPECT literature, several studies have reported
regional cerebral hypoperfusion in individuals with diabetes
(Last et al., 2007; Xia et al., 2015; Cui et al., 2017; Dai et al.,
2017), although some studies have reported no such differences
between individuals with and without diabetes (Launer et al.,
2015; Rusinek et al., 2015). Those studies that do report
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significant differences, however, have most consistently observed
associations between diabetes status and hypoperfusion in
posterior cortical regions (e.g., parietal regions) (Last et al., 2007;
Xia et al., 2015; Cui et al., 2017; Dai et al., 2017), although
some reports document hypoperfusion in frontal, temporal, and
limbic regions as well (Xia et al., 2015; Cui et al., 2017; Dai
et al., 2017). With respect to cognitive functioning in T2DM,
the ASL literature is even further limited. While the available
evidence suggests that alterations to CBF in certain regions are
associated with poorer cognitive functioning in individuals with
T2DM (Novak et al., 2014; Xia et al., 2015; Cui et al., 2017; Dai
et al., 2017), these data are extremely limited given the very few
published studies to date, and the findings are mixed with respect
to the affected cognitive domains.
Although there is mounting evidence to suggest an association
between T2DM, CBF, and cognition, prior studies lack the robust
methodology needed to reliably assess these associations. Many
studies do not specifically explore these associations in an older
adult population, despite this population being at an elevated risk
for both T2DM and dementia. Moreover, those that do target an
older sample employ ASL methods that are not optimized for
imaging CBF in older adults, which is problematic considering
that this population has expected increases in transport time
from the labeling position to the tissue (i.e., longer arterial transit
time) relative to younger adults and therefore the post-labeling
delay should be adjusted accordingly so that the CBF estimation
will not be biased by incomplete delivery of the labeled bolus
prior to image acquisition (Alsop et al., 2015). Finally, most
studies include relatively limited neuropsychological assessment.
Thus, the present study sought to extend the literature by
examining the associations among T2DM, CBF, and cognition
in a sample of well-characterized nondemented older adults
who underwent pseudo-continuous ASL imaging optimized for
older adult populations and comprehensive neuropsychological
assessment.
MATERIALS AND METHODS
Participants
Forty-nine independently living, nondemented older adults
were recruited from ongoing aging studies at the University
of California, San Diego (UCSD) and the San Diego VA
Healthcare System. Potential participants were excluded if they
were younger than 60 years of age; had a history of Type 1
diabetes; had dementia identified by medical, neurological, and
neuropsychological examinations; or had a history of stroke or
neurologic disease (e.g., Parkinson’s disease, multiple sclerosis),
head injury with cognitive sequelae, or major psychiatric
disorder; or for whom MRI was contraindicated (e.g., individuals
with a pacemaker). Of the 49 participants, 11 had T2DM, and 38
were nondiabetic control participants.
Ethics Statement
All participants provided written informed consent prior to
enrollment, and data were collected in accordance with ethical
standards for research. The UCSD and VA San Diego Healthcare
System Institutional Review Boards approved the research
protocol.
Clinical and Neuropsychological
Assessment
All participants underwent a semi-structured clinical interview
assessing medical and psychiatric history; assessment of
instrumental activities of daily living; physical examination with
brachial artery blood pressure measurement using an automated
blood pressure cuff; comprehensive neuropsychological testing;
and brain MRI. Participants were classified as having diabetes
based on self-report during clinical interview and review of
available medical records. Of the 11 participants with T2DM,
10 were being treated with antidiabetic medications (9 with oral
glucose lowering agents only and 1 with insulin only).
Presence of additional vascular risk factors included in the
Framingham stroke risk profile (FSRP) (D’Agostino et al.,
1994) was determined by self-report, medical chart review, and
physical examination. These vascular risk factors included: (1)
hypertension (defined as systolic blood pressure ≥140 mm Hg,
diastolic blood pressure ≥90 mm Hg, or use of antihypertensive
medications); (2) history of cardiovascular disease [e.g., coronary
artery disease (myocardial infarction, angina pectoris, coronary
insufficiency), intermittent claudication, cardiac failure]; (3)
atrial fibrillation; and (4) current cigarette smoking. To
characterize the aggregate vascular risk burden of our sample, we
also calculated a modified FSRP for each participant (D’Agostino
et al., 1994) omitting diabetes. Pulse pressure – a proxy for arterial
stiffness – was also calculated (as systolic minus diastolic blood
pressure), given that T2DM is associated with arterial stiffening
(Winer and Sowers, 2003; Tomiyama et al., 2005). Arterial
stiffening is also an AD risk factor that relates to AD cerebrospinal
fluid (CSF) biomarkers and cerebrovascular functioning (Nation
et al., 2015, 2016b; Werhane et al., 2018) including reduced CBF
(Yan et al., 2016).
Global cognition was assessed by the dementia rating scale
(DRS) (Mattis, 1988). Episodic memory was assessed by the
California Verbal Learning Test-Second Edition (CVLT-II) (Delis
et al., 2000) long delay free recall, and delayed recall of the Logical
Memory and Visual Reproduction subtests of the Wechsler
memory scale – revised (WMS-R) (Wechsler, 1987). Executive
function/processing speed was assessed using Trail Making Test,
Parts A and B. For each of the five cognitive scores, each
participant’s raw score was converted to a z-score based on the
mean and standard deviation of the entire sample (n = 49).
Domain composite scores are the mean of z-scores measured
within that domain. In addition, executive function/processing
speed composite scores were multiplied by –1 so that positive
z-scores represented better performance for all scores. Of note,
one participant with T2DM was missing CVLT-II data; one
nondiabetic control participant was missing WMS-R Logical
Memory data; and one T2DM participant was missing WMS-
R Visual Reproduction data. For these three participants who
were each missing data for one memory measure, their memory
composite score was calculated as the mean of their two
existing memory scores. In addition, two T2DM participants
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were missing both Trail Making Test variables and, therefore,
these individuals were not included in the analyses involving the
executive function/processing speed composite.
MRI Data Acquisition
Magnetic resonance imaging data were acquired on one of
two identical GE Discovery MR 750 3T whole body systems
using an 8-channel receive-only head coil (General Electric
Medical Systems, Milwaukee, WI, United States) at the UCSD
Keck Center for functional MRI. During scanning, participants
are provided with ear plugs and MRI-safe noise reduction
headphones and instructed to stay still. The scanner room is
dark and there is no visual stimulation. Participants are not given
instructions to keep their eyes open or closed. A T1-weighted
anatomical scan was acquired using a Fast Spoiled Gradient
Recall (3DFSPGR) sequence with the following parameters:
172.1 mm contiguous sagittal slices, field of view (FOV) = 25 cm,
repetition time (TR) = 8 ms, echo time (TE) = 3.1 ms, flip
angle = 12, inversion time (TI) = 600 ms, 256 × 192 matrix,
bandwidth = 31.25 kHZ, frequency direction = S–I, NEX = 1, scan
time = 8 min, and 13 s.
Resting CBF was acquired using a 2D pseudocontinuous ASL
(PCASL) sequence optimized for older adult populations, which
increases post-labeling delays to allow more time for the blood to
reach brain tissue with the following parameters: TR = 4,500 ms,
TE = 3.2 ms, FOV = 24 cm, labeling duration = 1,800 ms, post-
labeling delay = 2,000 ms, 24.6 mm slices, with a single shot spiral
acquisition and a total scan time of 4:18 min plus a 30 s calibration
scan. In addition, a spiral scan with the inversion pulses turned
off was acquired to obtain an estimate of the magnetization of
CSF. The CSF signal from this scan was used to estimate the
equilibrium magnetization of blood, which was used to convert
the perfusion signal into calibrated CBF units (i.e., millimeters
of blood per 100 g of tissue per minute) (Chalela et al., 2000).
A minimum contrast scan was also acquired to adjust for coil
inhomogeneities during the CBF quantification step (Wang et al.,
2005). Finally, a field map scan was also acquired and used
for off-line field map correction to help correct distortion and
signal dropout, particularly in the frontal and medial temporal
lobes.
MRI Data Processing
MRI data were processed using Analysis of Functional
NeuroImages (AFNI) (Cox, 1996), FMRIB Software Library
(FSL) (Smith et al., 2004), FreeSurfer, and locally created Matlab
scripts.
T1-Weighted Anatomical Images
T1-weighted anatomical images were processed using FreeSurfer
5.1 software. Briefly, images underwent skull stripping, B1
bias field correction, GM–WM segmentation, reconstruction of
cortical surface models, and parcellation and labeling of regions
on the cortical surface as well as segmentation and labeling of
subcortical brain structures (Dale et al., 1999; Fischl et al., 2002).
FreeSurfer output (gray–white boundary surface, pial surface,
cortical parcellation, and subcortical segmentation) was visually
inspected and, when necessary, manual edits were performed to
ensure proper region of interest (ROI) segmentation and GM and
WM differentiation.
ASL Images
Each participant’s raw ASL data (perfusion, CSF, and mincon
data), field map, and anatomical data were uploaded for
processing to the Cerebral Blood Flow Biomedical Informatics
Research Network (CBFBIRN1) (Shin et al., 2013) established at
the UCSD Center for Functional Magnetic Resonance Imaging).
Field map and motion correction; skull-stripping; and tissue
segmentation using FSL’s Automated Segmentation Tool (FAST)
algorithm to define CSF, GM, and WM tissue were completed.
The high-resolution T1-weighted image and partial volume
segmentations were then registered to ASL space, and partial
volume segmentations were down-sampled to the resolution of
the ASL data. To correct the CBF measures for partial volume
effects and ensure that CBF values were not influenced by known
decreased perfusion in WM or increased volume of CSF (Parkes
et al., 2004), we utilized the method described by Johnson et al.
(2005). These calculations assume that CSF has 0 CBF and that
CBF in GM is 2.5 times higher than that in WM. To compute
partial volume corrected CBF signal intensities, the following
formula was used: CBFcorr = CBFuncorr/(GM + 0.4 × WM)
where CBFcorr and CBFuncorr are corrected and uncorrected
CBF values, respectively, and GM and WM are the partial
volume fractions of GM and WM, respectively. The CBFcorr
data was blurred to 4.0 mm full-width at half maximum.
Each participant’s quantified CBF map (in units of mL/100 g
tissue/min) was downloaded to a local server and a threshold
was applied that removed values outside of the expected
physiological range of CBF (<10 or >150) (Bangen et al.,
2014).
FreeSurfer was used to generate anatomical ROIs for the CBF
data as well cortical thickness and volume data for these ROIs to
be compared between the T2DM and nondiabetic control groups.
We examined left and right hemisphere for the following five
a priori ROIs: (1) hippocampus, (2) inferior temporal cortex, (3)
inferior parietal cortex, (4) rostral middle frontal gyrus, and (5)
medial orbitofrontal cortex. These ROIs were selected because
they have been implicated in cerebrovascular dysfunction in MCI
and AD (Du et al., 2002; Nation et al., 2013, 2016a). Many of
these regions have been implicated in T2DM in the few existing
studies of ASL CBF in this population (Last et al., 2007; Xia
et al., 2015; Cui et al., 2017; Dai et al., 2017). The regional
GM CBF values (corrected for partial volume effects) from the
Desikan et al. (2006) atlas were extracted for each of the ROIs
for each hemisphere. See Figure 1 for a depiction of the a priori
ROIs used in the primary analyses. In addition, to adjust for
individual variation in CBF, postcentral gyrus CBF was used as a
reference region and included as a covariate in statistical analyses
comparing groups on CBF in the ROIs. This region was selected
due to its relative sparing in AD (Thompson et al., 2003) and
T2DM-related brain atrophy (Moran et al., 2013; Zhang et al.,
2014) as well as its use as a control region in our prior studies of
CBF in older adults at increased risk for AD (Bangen et al., 2017).
1cbfbirn.ucsd.edu
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FIGURE 1 | Regions of interest. (A) hippocampus; (B) rostral middle frontal gyrus (in green), inferior temporal cortex (in blue), and inferior parietal cortex (in yellow);
(C) medial orbitofrontal cortex (in orange).
FreeSurfer-derived intracranial volume was used as a covariate in
analyses comparing groups on regional brain volume.
In addition, groups were also compared on FreeSurfer-derived
volumes of WM signal abnormalities (WMSAs). WMSAs on MRI
refer to regions in the WM that appear hyperintense on T2
fluid-attenuated inversion recovery (FLAIR) but hypointense on
T1-weighted images. WMSAs are often observed in aging and
conditions including diabetes and are usually thought to reflect
small vessel CVD resulting from microvascular hypoperfusion
(Garde et al., 2000; O’Sullivan et al., 2002; Brickman et al.,
2015; Shen et al., 2017). The FreeSurfer automated segmentation
pipeline subdivides brain tissue into regions of GM, WM, and
hypointense regions within the WM using a combination of
segmentation and a set of anatomical priors (Fischl and Dale,
2000; Fischl et al., 2002). Total volume of WM hypointensities
was extracted from FreeSurfer output.
Statistical Analyses
Analysis of variance (ANOVA) and chi-square tests were used
to compare those with and without T2DM on demographic
and clinical characteristics of interest. Multiple analysis of
covariance (MANCOVA) models were used to determine CBF
and structural brain differences between T2DM and nondiabetic
control participants. The MANCOVA compared CBF in the
selected ROIs adjusting for age, sex, modified FSRP (omitting
diabetes), and reference CBF (postcentral gyrus). The modified
FSRP was used as a covariate in an effort to determine whether
any potential groups differences in CBF were related to T2DM
rather than possible comorbid vascular risk factors/conditions.
This composite measure to assess vascular risk (rather than
individuals vascular risk factors) was used to maximize the
sample size to independent variable ratio in our analyses.
MANCOVAs were also used to determine whether there were
group differences in brain structure (i.e., cortical thickness or
volume) that might influence CBF findings, particularly given
that some previous studies have reported that atrophy may largely
explain lower CBF in T2DM (Sabri et al., 2000). One MANCOVA
compared cortical thickness in 4 of the 5 ROIs (inferior parietal
cortex, inferior parietal cortex, rostral middle frontal gyrus, and
medial orbitofrontal cortex) adjusting for age, sex, and modified
FSRP. A second MANCOVA compared volume of hippocampus
and WM hypointensities adjusting for age, sex, modified FSRP,
and intracranial volume. All a priori ROIs were entered into the
MANCOVAs simultaneously.
Pearson’s product-moment correlations examined the
associations between cognition and CBF across the entire
sample (i.e., collapsed across T2DM and nondiabetic control
participants). To minimize comparisons, we examined
associations only for those unilateral ROIs that showed
significant group differences in CBF. For each significant ROI,
we correlated regional CBF with performance in cognitive
domains subserved by that region. Specifically, we examined
the associations of the memory composite score and CBF in
the hippocampus and inferior temporal cortex. In addition, we
examined the associations of the executive function/processing
speed composite with CBF in the inferior parietal cortex and
rostral middle frontal gyrus.
Sensitivity analyses were performed to determine whether
results from the primary analyses may have been influenced
by potential sex-related CBF differences and/or the presence
of comorbid vascular risk factors associated with T2DM (e.g.,
hypertension). First, we compared men and women (regardless
of T2DM status) on mean CBF for regions where differences were
observed between the T2DM and nondiabetic control groups.
Second, we ran t-test analyses to compare a subset of the sample
consisting of nondiabetic control participants (n = 11) and T2DM
(n = 11) participants who were matched so that the two groups
did not significantly differ in terms of demographic or covariate
variables. Significance levels of 0.05 were used for all analyses. All
statistical analyses were conducted using the Statistical Package
for the Social Sciences (SPSS) version 24 (SPSS IBM, New York,
United States).
Finally, in order to address potential inflation of type I error
resulting from multiple comparisons, we applied the Benjamini–
Hochberg procedure (Benjamini and Hochberg, 1995). We
assessed results when the false discovery rate (FDR) was
controlled at 0.05 and 0.10.
RESULTS
Participant Characteristics
Participant demographics and clinical characteristics are
presented in Table 1. In comparison to the nondiabetic control
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TABLE 1 | Demographic and neuropsychological characteristics by T2DM status.
Nondiabetic T2DM F or χ2 p Effect size
(n = 38) (n = 11)
Demographics∗
Age, years 73.6 (5.9) 72.3 (2.8) 0.49 0.486 ηp2 = 0.010
Education, years 17.0 (1.7) 16.6 (2.4) 0.24 0.627 ηp2 = 0.005
Sex, M:F 13:25 8:3 5.17 0.023 ϕc = 0.325
FSRP (%)∗∗ 10.1 (7.9) 13.4 (7.8) 1.47 0.232 ηp2 = 0.030
Pulse pressure, mmHg 50.5 (11.2) 56.2 (16.1) 1.86 0.179 ηp2 = 0.038
Current smoker (%) 5.3 9.1 0.22 0.641 ϕc = 0.067
History of cardiovascular disease (%) 5.3 9.1 0.22 0.641 ϕc = 0.067
History of hypertension (%) 52.6 100.0 8.24 0.004 ϕc = 0.410
History of atrial fibrillation (%) 10.5 9.1 0.02 0.890 ϕc = 0.020
GDS 3.6 (3.9) 6.1 (3.7) 3.31 0.075 ηp2 = 0.069
Cognitive measures∗∗∗
Mean (SD)
Global cognition (DRS total score) 140.5 (3.4) 138.3 (4.5) 0.94 0.338 ηp2 = 0.021
Memory composite 0.18 (0.8) −0.78 (0.9) 5.80 0.020 ηp2 = 0.117
Executive function/processing speed composite 0.20 (0.7) −0.83 (1.1) 11.72 0.001 ηp2 = 0.218
T2DM, type 2 diabetes mellitus; SD, standard deviation; FSRP, Framingham stroke risk profile (D’Agostino et al., 1994); GDS, geriatric depression scale; DRS, Mattis
dementia rating scale (Mattis, 1988).
∗Data are mean and standard deviation in parentheses unless otherwise noted.
∗∗Modified FSRP omitting diabetes.
∗∗∗DRS total score is a raw score (maximum possible score = 144); memory and executive function/processing speed composite scores are z scores. Results for the
group comparisons on DRS and memory and executive function/processing speed composite scores are from analysis of covariance (ANCOVA) models adjusted for age,
sex, and education.
group, the T2DM group had a greater proportion of men relative
to women and a greater proportion of individuals with a history
of hypertension relative to those with no history of hypertension.
There were no significant group differences with respect to
mean age, education, aggregate vascular risk (i.e., modified
FSRP omitting diabetes), pulse pressure, current smoking status,
history of cardiovascular disease, history of atrial fibrillation, and
depression. There were no significant group differences in global
cognition as assessed by DRS total score. In contrast, those with
T2DM performed significantly worse on the memory composite
score and the executive function/processing speed composite
score.
Regional CBF by T2DM
Group means and differences in CBF for a priori ROIs are shown
in Figure 2. MANCOVA adjusting for age, sex, aggregate vascular
risk (i.e., modified FSRP omitting diabetes), and reference CBF
(postcentral gyrus) revealed significant effects of T2DM on
regional CBF. Specifically, compared to nondiabetic control
participants, individuals with T2DM exhibited lower CBF in
left hippocampus [F(1,43) = 5.45, p = 0.024, η2p = 0.113], right
hippocampus [F(1,43) = 8.81, p = 0.005, η2p = 0.170], right inferior
parietal cortex [F(1,43) = 11.78, p = 0.001, η2p = 0.215], right
inferior temporal cortex [F(1,43) = 8.00, p = 0.007, η2p = 0.157],
and right rostral middle frontal gyrus [F(1,43) = 9.38, p = 0.004,
η2p = 0.179]. Statistical significance of all results described above
was retained using a 0.05 FDR.
In contrast, there were no significant group differences for left
inferior parietal cortex [F(1,43) = 0.01, p = 0.906, η2p < 0.001], left
inferior temporal cortex [F(1,43) = 2.01, p = 0.163, η2p = 0.045],
left medial orbitofrontal cortex [F(1,43) = 0.16, p = 0.690,
η2p = 0.004], right medial orbitofrontal cortex [F(1,43) = 0.02,
p = 0.903, η2p < 0.001], or left rostral middle frontal gyrus
[F(1,43) = 1.88, p = 0.178, η2p = 0.042]. Also, as expected, we
confirmed that there were no group differences in terms of
postcentral gyrus reference CBF [F(1,47) = 0.78, p = 0.382,
η2p = 0.016].
Regional Cortical Thickness and Volume
by T2DM
Multiple analysis of covariance models adjusting for age, sex, and
aggregate vascular risk (i.e., modified FSRP omitting diabetes)
(and intracranial volume for analyses with hippocampal volume
and WM hypointensities as the dependent variable) examined
differences in cortical thickness or volume for the a priori ROIs
used in the CBF analyses as well as for WM hypointensities.
These models revealed no significant group differences in
terms of cortical thickness of the right or left inferior parietal
cortices [left: (F(1,44) = 0.58, p = 0.452, η2p = 0.013); right:
(F(1,44) = 0.50, p = 0.502, η2p = 0.010)], inferior temporal
cortices [left: (F(1,44) = 0.27, p = 0.607, η2p = 0.006); right:
(F(1,44) = 0.17, p = 0.687, η2p = 0.004)], medial orbitofrontal
cortices [left: (F(1,44) = 0.003, p = 0.955, η2p < 0.001); right:
(F(1,44) = 0.37, p = 0.545, η2p = 0.008)], or rostral middle
frontal gyri [left: (F(1,44) = 1.44, p = 0.237, η2p = 0.032); right:
(F(1,44) = 0.94, p = 0.337, η2p = 0.021)]. Similarly, there were
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FIGURE 2 | Mean regional CBF for T2DM and nondiabetic control groups. CBF, cerebral blood flow; L, left; R, right; hipp, hippocampus; ITC, inferior temporal
cortex; IPC, inferior parietal cortex; rMFG, rostral middle frontal gyrus; mOFC, medial orbitofrontal cortex. ∗p < 0.05. Error bars represent ± 1 standard error.
no significant differences between those with T2DM and the
nondiabetic control participants in left or right hippocampal
volume [left: (F(1,43) = 1.32, p = 0.258, η2p = 0.030); right:
(F(1,43) = 2.06, p = 0.158, η2p = 0.046)] or volume of WM
hypointensities [F(1,43) = 0.83, p = 0.367, η2p = 0.019].
Associations Between Regional CBF and
Cognition
Correlation analyses were used to examine associations between
CBF (in regions for which group differences were found
by T2DM status) and cognitive abilities subserved by those
particular regions. That is, analyses were performed relating
bilateral hippocampal and right inferior temporal CBF to
memory and right inferior parietal and right rostral middle
frontal CBF to executive function/processing speed. Associations
were examined both unadjusted and controlling for diabetes
status (present versus absent).
Collapsed across the entire sample, there were significant
associations between lower regional CBF and poorer cognitive
performance (see Figure 3 for selected associations for memory
and executive function/processing speed with regional CBF).
Lower hippocampal and inferior temporal cortex CBF was
associated with poorer memory performance. Significant CBF-
memory correlations were found for both left hippocampal
CBF (r = 0.31, p = 0.016) and right hippocampal CBF
(r = 0.25, p = 0.044). In contrast, lower right inferior temporal
CBF was not significantly associated with poorer memory
performance (r = 0.07, p = 0.310). Significant associations were
maintained when FDR was limited to 0.10. In contrast, the
association with memory and left hippocampal CBF but not right
hippocampal CBF remained significant when FDR was limited to
0.05.
When partial correlations adjusted for diabetes status were
performed, the associations between regional CBF and memory
were attenuated and no longer statistically significant (left
hippocampus: r = 0.15, p = 0.168; right hippocampus: r = 0.02,
p = 0.458; right inferior temporal gyrus: r =−0.10, p = 0.253).
Lower CBF in right inferior parietal cortex and rostral
middle frontal gyrus was associated with poorer performance on
measures of executive function/processing speed (right inferior
parietal cortex: r = 0.36, p = 0.007; right rostral middle frontal
gyrus: r = 0.34, p = 0.009). These significant associations were
maintained when FDR was limited to 0.05.
When partial correlation analyses were performed adjusting
for diabetes status, the associations between regional CBF and
executive function/processing speed were somewhat attenuated
although they remained statistically significant for both the right
inferior parietal cortex (r = 0.26, p = 0.043) and right rostral
middle frontal gyrus (r = 0.29, p = 0.028).
Sensitivity Analyses
Given the higher proportion of men in the T2DM group, we
performed sensitivity analyses to examine the potential role of sex
on CBF in our sample. Similar to our primary analyses examining
CBF by T2DM status, we ran MANCOVA models adjusting
for age, aggregate vascular risk (i.e., modified FSRP omitting
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FIGURE 3 | Scatterplots of correlations between cognitive composite scores (z-scores) and regional cerebral blood flow (in units of milliliters per 100 g of tissue per
minute). (A) Depicts the correlation between memory performance and left hippocampal CBF and (B) the correlation between executive function/processing speed
and inferior parietal CBF (all p’s < 0.05). These significant associations were maintained controlling the FDR at 0.05. When partial correlation analyses were
performed adjusting for diabetes status, the association between executive function/processing speed and regional CBF remained statistically significant (p < 0.05)
whereas the association between memory and regional CBF was no longer significant.
diabetes), and reference CBF (postcentral gyrus) to assess sex-
related differences in CBF for those regions where group
differences were observed between the nondiabetic controls
and T2DM participants. The MANCOVA models revealed no
significant differences between men and women across any
of these ROIs [left hippocampus: (F(1,44) = 0.04, p = 0.848,
η2p = 0.001); right hippocampus: (F(1,44) = 0.54, p = 0.465,
η2p = 0.012); right inferior parietal: (F(1,44) = 1.62, p = 0.210,
η2p = 0.035); right inferior temporal: (F(1,44) = 0.75, p = 0.393,
η2p = 0.017); right rostral middle frontal: (F(1,44) = 0.57,
p = 0.454, η2p = 0.013)].
In addition, we also performed t-test analyses to compare a
subset of the sample consisting of nondiabetic control (n = 11)
and T2DM (n = 11) participants who were matched so that the
two groups did not significantly differ in terms of demographic
or covariate variables including age; sex; aggregate vascular
risk; pulse pressure, systolic blood pressure, or diastolic blood
pressure; history of cardiovascular disease or atrial fibrillation;
or depression (i.e., GDS score). In this matched subsample,
findings for group differences in CBF remained statistically and
qualitatively similar to the results from analyses including the
entire sample. That is, when the T2DM and nondiabetic control
groups were equivalent in terms of sex distribution and vascular
risk covariates, the T2DM participants showed reduced CBF in
left hippocampus (t = 3.29, p = 0.004, Cohen’s d = 1.40), right
hippocampus (t = 4.10, p = 0.001, Cohen’s d = 1.75), right inferior
parietal cortex (t = 2.68, p = 0.014, Cohen’s d = 1.14), right inferior
temporal cortex (t = 2.90, p = 0.009, Cohen’s d = 1.24), and right
rostral middle frontal gyrus (t = 2.85, p = 0.104, Cohen’s d = 1.21).
Similar to the primary analyses including the entire sample, there
were no significant group differences in any of the other a priori
ROIs (left inferior parietal cortex: t = 0.95, p = 0.352, Cohen’s
d = 0.41; left inferior temporal cortex: t = 1.63, p = 0.118, Cohen’s
d = 0.70; left medial orbitofrontal cortex t = 1.21, p = 0.240,
Cohen’s d = 0.52; right medial orbitofrontal cortex: t = 0.75,
p = 0.462, Cohen’s d = 0.32; left rostral middle frontal cortex:
t = 1.74, p = 0.097, Cohen’s d = 0.74).
DISCUSSION
Our results demonstrate that CBF is reduced in nondemented
older adults with T2DM independent of age, sex, and related
vascular risk factors. We did not find significant differences
between those with and without T2DM in terms of brain
structure (cortical thickness or brain volume in regions of
interest), suggesting that CBF alterations occur independent of
cerebral atrophy and may precede structural changes that have
been identified in previous studies. T2DM-related reductions
in CBF were pronounced in known predilection sites for AD
pathology as well as regions implicated in cerebrovascular
dysfunction in early AD (hippocampus, inferior parietal cortex,
inferior temporal cortex, and middle frontal regions). Moreover,
among older adults both with and without T2DM, lower
CBF was associated with poorer cognitive performance in
memory and executive/processing speed domains. These findings
were somewhat attenuated when analyses were adjusted for
diabetes status although associations between regional CBF
and executive function/processing speed remained significant
in adjusted analyses. Findings add to a growing body of
research suggesting that perfusion deficits may underlie cognitive
decrements frequently observed among older adults with T2DM.
Results also suggest that CBF measured with ASL MRI may reflect
an early and important marker of risk of cognitive decline in
T2DM and related conditions particularly given that the mean
level of performance on cognitive measures in our sample was
within the normal range and not objectively impaired.
Several previous studies have examined the association of
T2DM and CBF using techniques including PET, SPECT, and
ASL, although findings across studies have been mixed. Many
studies have reported reduced CBF in T2DM (Last et al., 2007;
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Xia et al., 2015; Cui et al., 2017; Dai et al., 2017), although some
other studies have reported no differences between individuals
with and without T2DM (Tiehuis et al., 2008; Launer et al.,
2015; Rusinek et al., 2015). As noted by Dai et al. (2017), studies
reporting no alterations in CBF in T2DM relative to nondiabetic
control participants typically examined large ROIs such as whole
brain GM or large cortical regions. Importantly, previous studies
are limited in their ability to reliably detect CBF reductions in the
context of T2DM as they typically did not consider the effects of
additional vascular risk factors such as hypertension (Dai et al.,
2017) or elevated pulse pressure, which commonly co-occur with
T2DM, or brain atrophy, which in some instances appears to fully
account for decreased CBF (Sabri et al., 2000). Furthermore, few
studies have utilized a PCASL sequence and implemented an ASL
protocol optimized for use in older adults.
Despite previous findings linking T2DM and elevated blood
glucose to cognitive impairment and AD, there are few studies
investigating the neuropathologic mechanisms underlying these
associations. Although autopsy-based studies have shown that
T2DM is linked to cerebral infarcts (Peila et al., 2002;
Arvanitakis et al., 2006; Sarwar et al., 2010), its association
with AD neuropathology itself (i.e., β-amyloid plaques, Aβ and
neurofibrillary tangles, NFT) remains unclear. (Peila et al., 2002;
Beeri et al., 2005; Arvanitakis et al., 2006; Ahtiluoto et al., 2010;
Malek-Ahmadi et al., 2013). However, some evidence suggests
a role for deficiencies in brain insulin in the pathogenesis of
AD and have proposed that AD may be “type 3 diabetes” (Steen
et al., 2005). In our previous work, we found that midlife elevated
blood glucose is predictive of more severe AD pathology (i.e.,
higher medial temporal lobe NFT pathology) in late life. This
work suggests that elevated blood glucose – even many years
before death and even among nondiabetic individuals – may have
detrimental effects on the brain that ultimately contribute to the
development of AD pathology and subsequent cognitive decline
(Bangen et al., 2016). The present findings provide additional
evidence for the influence of T2DM on changes in AD-vulnerable
regions, and they suggest that cerebrovascular dysfunction may
underlie the predilection of AD pathology in these regions.
We found lower CBF in T2DM in a priori ROIs including
medial temporal lobe, parietal, and frontal regions. This pattern is
similar to that seen in AD and vascular disease. Medial temporal
regions are susceptible to early pathologic and neurodegenerative
changes in AD, and alterations in CBF represent a potential
mechanism through which these changes may occur. Indeed,
many of the regions implicated in the current study, including
inferior parietal cortices, are key components of the default mode
network, which contributes to episodic memory and executive
functioning and has been implicated in preclinical AD (Hampel,
2013). Lifetime cerebral metabolism associated with default mode
network activity may predispose these regions to AD-related
pathologic changes including Aβ accumulation and may also
disrupt connections with the medial temporal lobe, resulting in
impaired cognitive function (Buckner et al., 2005). Further, WM
lesion pathology in the parietal lobe has been implicated as an
early biomarker of AD, and as a marker of small-vessel disease,
these lesions may reflect later-stage consequences of chronic
hypoperfusion in this region (Lee et al., 2016).
The present findings corroborate previous studies
demonstrating hypoperfusion in T2DM in the absence of
brain volume differences, suggesting that perfusion alterations
are independent of cerebral atrophy (Xia et al., 2015; Jansen
et al., 2016). Previous studies have shown that functional changes
precede structural changes in the context of AD (Devous, 2002)
and T2DM (Musen et al., 2012). Given this, MRI techniques
such as ASL have great potential as a non-invasive method
for detecting early and/or subtle functional brain changes in
asymptomatic individuals. Advanced MRI techniques that
measure early physiological changes including alterations in CBF
may elucidate the mechanisms that precede the development
of irreversible parenchymal/structural damage and serve as a
marker of risk for cognitive decline.
Indeed, mounting evidence suggests that ASL CBF represents
a useful biomarker in at-risk individuals given that this technique
can reliably differentiate those at risk from control participants
(Fleisher et al., 2009; Bangen et al., 2012; Wierenga et al., 2012).
Furthermore, longitudinal studies have shown that ASL CBF
indices predict cognitive decline in older adults with normal
cognition (Xekardaki et al., 2015) as well as progression from
normal cognition to MCI (Beason-Held et al., 2013), and MCI
to AD (Chao et al., 2010). Previous work has shown that CBF
alterations are independent of changes in volume and were
detectable several years prior to the development of cognitive
impairment (Beason-Held et al., 2013). Our current findings
emphasize the important link between CBF and cognition,
and they provide further support for CBF as a useful marker
of vascular risk and correlate of cognitive functioning in
nondemented older adults. Furthermore, a recent study showed
that there was an increase in perfusion and improvements in
cognitive performance after insulin administration in individuals
with T2DM which was greater than in the nondiabetic control
group, and these insulin-induced changes were associated with
vasodilation in the middle cerebral artery territory, suggesting
involvement of a vascular mechanism (Novak et al., 2014).
Although findings have been mixed, overall it appears that
reduced CBF seems to be an early change independent of
brain structural changes and may be a viable intervention target
for preventing cognitive decline in T2DM. Dissemination of
methods capable of detecting cerebrovascular dysfunction prior
to the manifestation of these frank lesions would represent
a major advancement in early detection and expansion of
treatment opportunities to prevent or delay cognitive impairment
in these individuals.
Taken together, our findings show an important relationship
between cerebral perfusion and memory and executive function
in the context of T2DM. Results further highlight the potential
value in examining ASL CBF as a sensitive vascular marker in
aging, metabolic and vascular conditions, and dementia risk.
Strengths of this work include a well-characterized sample,
comprehensive neuropsychological assessment, and use of an
ASL protocol optimized for use in older adults. However, there
are important limitations of this study worth noting. First, our
sample size of participants with T2DM is small and thus results
should be considered preliminary. Data on glycemic control was
not available (e.g., hemoglobin A1c) and therefore not included
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in our analyses, which should be addressed in future studies.
In addition, our sample was predominantly white, generally
medically healthy, and relatively well-educated, which may affect
generalizability of the findings. Future studies should include
larger sample sizes and longitudinal follow-up spanning middle
age to older age in order to better understand how changes in CBF
may evolve over time and how they influence the development of
later-stage structural and pathologic changes that have previously
been associated with T2DM. Finally, the nondiabetic control
group included a higher proportion of women relative to the
T2DM group. Although women have been shown to have higher
CBF, some evidence suggests that this difference is diminished
with advancing age and that, by the sixth decade, men and
women show similar CBF rates (Gur et al., 1987; Gur and Gur,
1990). The mean age of the present sample was approximately 73
(range = 68–88). We performed sensitivity analyses to examine
the potential role of sex on CBF in our sample and found that sex
was not significantly associated with regional CBF. We performed
a second set of sensitivity analyses in a subset of our sample
including nondiabetic control participants and those with T2DM
who were matched on distribution of sex, pulse pressure and
blood pressure, and other important demographic and vascular
risk variables. Findings were qualitatively and statistically similar
to those from the primary analyses including the entire sample.
Nonetheless, future work should aim to replicate our findings in
a larger sample with groups matched on sex distribution.
Despite these limitations, our findings, if replicated, may
have important research and clinical implications. Indeed, our
results show that reduced CBF may be an early marker of
incipient change independent of brain structural changes, and
it may be a viable intervention target for preventing cognitive
decline in T2DM. Dissemination of methods capable of detecting
cerebrovascular dysfunction prior to the manifestation of these
frank lesions would represent a major advancement in early
detection and expansion of treatment opportunities to prevent
or delay cognitive impairment in these individuals. For example,
pharmacological and behavioral interventions, such as physical
exercise, may influence the regulation of CBF and, ultimately, the
prevention of cognitive decline in T2DM and related conditions.
T2DM is a growing condition that has been linked to the
development of substantial cognitive and brain changes, and
there is therefore a pressing public health need to identify early
biomarkers of cognitive decline in T2DM and related conditions
as well as potentially modifiable mechanisms underlying these
changes. Such research will help facilitate the development and
optimization of targeted interventions to reduce dementia risk
while improving the health and functioning of individuals with
T2DM and other groups at risk for cognitive decline.
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